enpp-1

Enpp-1-IN-16 is an inhibitor targeting ENPP1 with potential anti-cancer activity.Enpp-1-IN-16 can be used to study insulin resistance in relation to type II diabetes mellitus and various ENPP1-mediated diseases in the chondrocalcinosis and osteoarthritis classes.

Enpp-1-IN-14 is a potent inhibitor of Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity.

Enpp-1-IN-1 is an inhibitor of Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1)

Enpp-1/3-IN-1 (Compound 5j) serves as an inhibitor for ENPP1 and ENPP3, with IC50 values of 0.59 μM for h-ENPP1 and 0.62 μM for h-ENPP3, respectively. This compound also inhibits e5′NT (CD73) and TNAP, exhibiting IC50 values of 0.89 μM for h-e5′NT, 5.12 μM for r-e5′NT, and 1.68 μM for h-TNAP. Enpp-1/3-IN-1 is applicable in cancer research.

ENPP1 Inhibitor C is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor with potential anticancer activity for the study of triple-negative breast cancer.

ENPP1 inhibitor 32 is an ENPP1 inhibitor with antitumor activity.

ENPP1 inhibitor 43 is a novel small molecule for cancer immunotherapy.

Enpp-1-IN-23 (compound 27) is an Enpp-1 inhibitor with an IC50 value of 1.2 nM. This compound is utilized in cancer research.

Enpp-1-IN-24 (compound 7) is an ENPP1 inhibitor that, when used in combination with anti-PD-1 antibodies, achieves a tumor growth inhibition rate of 77.7% and enhances survival rates in a mouse model.

Enpp-1-IN-21 (compound 4g) is an inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), with IC50 values of 0.45 μM for ENPP1 and 0.19 μM for ENPP3.

Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and exhibits low oral bioavailability. By inhibiting cGAMP degradation, it effectively activates the intracellular STING pathway. Enpp-1-IN-25 can enhance immune cell infiltration and type I interferon response in the tumor microenvironment, thereby increasing the antitumor efficacy of anti-PD-L1 antibodies. It is applicable for research in cancer immunotherapy.

Enpp-1-IN-20 (Compound 31) is an inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) with an IC50 of 0.09 nM. It demonstrates the most potent inhibitory activity in cell assays, with an IC50 of 8.8 nM. Enpp-1-IN-20 significantly inhibits ENPP1 in vitro and activates the STING pathway. This compound can be utilized in cancer research.

Enpp-1-IN-26 (Compound 4e) is an ENPP1 inhibitor with an IC50 value of 0.188 μM. By preventing ENPP1 from hydrolyzing cGAMP, Enpp-1-IN-26 enhances the expression levels of IFN-β in vivo and can be used in studies on metastatic breast cancer.

Enpp-1-IN-28 is an ENPP1 inhibitor with IC50 values of 0.188 µM at the molecular level and 0.732 µM at the cellular level. By preventing ENPP1 from hydrolyzing cGAMP, Enpp-1-IN-28 enhances the expression level of IFN-β in vivo, thereby triggering a stronger innate immune response. Enpp-1-IN-28 is applicable in metastatic breast cancer research.

Enpp-1-IN-27 is a selective ENPP1 inhibitor with an IC50 of 14.68 nM, exhibiting approximately 410-fold selectivity over ENPP2 and roughly 10-fold selectivity over ENPP3. This compound stabilizes cGAMP levels and activates the STING pathway, leading to cytokine release and an enhanced innate immune response. In addition, Enpp-1-IN-27 activates ISRE and boosts cGAMP-mediated immune responses, demonstrating significant antitumor effects in 4T1 and CT26 syngeneic mouse models. It is applicable to breast cancer and colon cancer research.

Enpp-1-IN-29 (Compound 1) is a highly selective inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) with an IC50 of 0.05 nM. This compound shows potential for research into cancers with overexpressed ENPP1, such as breast cancer, head and neck cancer, and metastatic chromosomal instability tumors, as well as immunological disorders like autoimmune diseases and tumor immune evasion.

Enpp-1-IN-30 (compound 44a) is an ENPP1 inhibitor with oral bioavailability and a human IC50 of 13.1 nM. It prevents cGAMP degradation and activates the STING pathway. Enpp-1-IN-30 induces cytokine release to enhance the innate immune response and demonstrates antitumor efficacy in syngeneic mouse models. This compound is applicable for colon cancer research.

Enpp-1-IN-10 (compound 1) is a potent inhibitor of Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1) with a Ki value of 3.866 μM, suitable for anticancer research [1].

Enpp-1-IN-11 (compound 23) is a highly potent inhibitor of Ecto-nucleotide pyrophosphatase/phosphodiesterases 1 (ENPP1), with a Ki value of 45 nM. It demonstrates excellent stability in human and mouse plasma and exhibits low clearance in both human and mouse liver microsomes, holding promise for anticancer research [1].

Enpp-1-IN-12 (compound 43), an orally active and potent inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) with a K_i of 41 nM, exhibits anti-tumor activity [1].

Enpp-1-IN-9, a powerful inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1), exhibits wide substrate specificity, capable of cleaving various bonds such as phosphodiester bonds of nucleotides and nucleotide sugars, as well as pyrophosphate bonds of nucleotides and nucleotide sugars. Its potential application lies in the fields of cancer and infectious disease research[1].

Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1), which exhibits broad specificity, capable of cleaving phosphodiester bonds of nucleotides and nucleotides, as well as pyrophosphate bonds of nucleotides and nucleotides. Enpp-1-IN-5 has potential applications in cancer and infectious disease research.

Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) with potential for cancer disease studies.

Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1), which has broad specificity and cleaves a wide range of substrates, including phosphodiester bonds and pyrophosphate bonds of nucleotides and nucleotides. Enpp-1-IN-7 has potential applications in cancer and infectious disease research.